PMID- 26512632
OWN - NLM
STAT- MEDLINE
DCOM- 20160815
LR  - 20231005
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 20
IP  - 10
DP  - 2015 Oct 23
TI  - Highly Selective Bioconversion of Ginsenoside Rb1 to Compound K by the Mycelium 
      of Cordyceps sinensis under Optimized Conditions.
PG  - 19291-309
LID - 10.3390/molecules201019291 [doi]
AB  - Compound K (CK), a highly active and bioavailable derivative obtained from 
      protopanaxadiol ginsenosides, displays a wide variety of pharmacological 
      properties, especially antitumor activity. However, the inadequacy of natural 
      sources limits its application in the pharmaceutical industry. In this study, we 
      firstly discovered that Cordyceps sinensis was a potent biocatalyst for the 
      biotransformation of ginsenoside Rb1 into CK. After a series of investigations on 
      the biotransformation parameters, an optimal composition of the biotransformation 
      culture was found to be lactose, soybean powder and MgSO(4) without controlling the 
      pH. Also, an optimum temperature of 30  degrees C for the biotransformation process was 
      suggested in a range of 25  degrees C-50  degrees C. Then, a biotransformation pathway of 
      Rb1-->Rd-->F2-->CK was established using high performance liquid 
      chromatography/quadrupole time-of-flight mass spectrometry (HPLC-Q-TOF-MS). Our 
      results demonstrated that the molar bioconversion rate of Rb1 to CK was more than 
      82% and the purity of CK produced by C. sinensis under the optimized conditions 
      was more than 91%. In conclusion, the combination of C. sinensis and the 
      optimized conditions is applicable for the industrial preparation of CK for 
      medicinal purposes.
FAU - Wang, Wei-Nan
AU  - Wang WN
AD  - School of Pharmaceutical Sciences, Changchun University of Chinese Medicine, 
      Changchun 130117, China. cnweinanwang@163.com.
FAU - Yan, Bing-Xiong
AU  - Yan BX
AD  - School of Pharmaceutical Sciences, Changchun University of Chinese Medicine, 
      Changchun 130117, China. ybx10528@163.com.
FAU - Xu, Wen-Di
AU  - Xu WD
AD  - School of Pharmaceutical Sciences, Changchun University of Chinese Medicine, 
      Changchun 130117, China. 15584452505@163.com.
FAU - Qiu, Ye
AU  - Qiu Y
AD  - School of Pharmaceutical Sciences, Changchun University of Chinese Medicine, 
      Changchun 130117, China. ccqy19890810@163.com.
FAU - Guo, Yun-Long
AU  - Guo YL
AD  - School of Pharmaceutical Sciences, Changchun University of Chinese Medicine, 
      Changchun 130117, China. ccyunlong1016@126.com.
FAU - Qiu, Zhi-Dong
AU  - Qiu ZD
AD  - School of Pharmaceutical Sciences, Changchun University of Chinese Medicine, 
      Changchun 130117, China. qiuzd@ccucm.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151023
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (Culture Media)
RN  - 0 (Ginsenosides)
RN  - 7413S0WMH6 (ginsenoside Rb1)
RN  - A9RLM212CY (ginsenoside M1)
SB  - IM
MH  - Biotransformation
MH  - Cordyceps/growth & development/*metabolism
MH  - Culture Media
MH  - Ginsenosides/*biosynthesis/isolation & purification/*metabolism
MH  - Hydrogen-Ion Concentration
MH  - Hydrolysis
MH  - Metabolic Networks and Pathways
MH  - Mycelium/growth & development/*metabolism
PMC - PMC6332142
OTO - NOTNLM
OT  - Cordyceps sinensis
OT  - biotransformation
OT  - compound K
OT  - ginsenoside Rb1
OT  - optimization
COIS- The authors declare no conflict of interest.
EDAT- 2015/10/30 06:00
MHDA- 2016/08/16 06:00
PMCR- 2015/10/23
CRDT- 2015/10/30 06:00
PHST- 2015/08/10 00:00 [received]
PHST- 2015/10/01 00:00 [revised]
PHST- 2015/10/02 00:00 [accepted]
PHST- 2015/10/30 06:00 [entrez]
PHST- 2015/10/30 06:00 [pubmed]
PHST- 2016/08/16 06:00 [medline]
PHST- 2015/10/23 00:00 [pmc-release]
AID - molecules201019291 [pii]
AID - molecules-20-19291 [pii]
AID - 10.3390/molecules201019291 [doi]
PST - epublish
SO  - Molecules. 2015 Oct 23;20(10):19291-309. doi: 10.3390/molecules201019291.